Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
J Interferon Cytokine Res 2011;31(9):653-659
Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications
The reduced caloric deficit (300-500 calories versus 800 calories with higher doses) results in more gradual but sustainable weight management
Learn More 3 Start your plan If eligible, your plan may include compounded GLP-1 medication with pharmacy coordination, ongoing oversight, and direct-to-door delivery
Getting the full picture A change in sex drive on GLP-1 therapy is not something to ignore or assume will resolve on its own
US$ 25.84
US$ 25.27
US$ 26.63
US$ 24.74
US$ 21.58
US$ 29.05
